FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Joel Gallant

Research Profile

Disorders

Chemicals & Drugs

Procedures

Concepts & Ideas

Living Beings

HIV-1
HIV

Physiology

Viral Drug Resistance

Co-author Network

Publications

TOP 3
Andrew R Zolopa; Andrew K Cheng; Calvin Cohen; Edwin DeJesus; Joel E Gallant; Hui C Liu; Anthony Mills; Andrew Plummer; Martin S Rhee; Paul E Sax; Javier Szwarcberg; Kirsten L White; David Wohl
A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results.
Derek M Fine; Joel E Gallant
Nephrotoxicity of antiretroviral agents: is the list getting longer?
Arata Honda; Koichi Kashiwazaki; Takafumi Tsunoda; Joel E Gallant; Todd T Brown
Short communication: CD4 cell count increases during successful treatment of Graves' disease with methimazole in HIV-infected patients on antiretroviral therapy.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Joel Gallant (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Andrew R Zolopa; Andrew K Cheng; Calvin Cohen; Edwin DeJesus; Joel E Gallant; Hui C Liu; Anthony Mills; Andrew Plummer; Martin S Rhee; Paul E Sax; Javier Szwarcberg; Kirsten L White; David Wohl
A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results.
Journal of acquired immune deficiency syndromes (1999) 2013;63(1):96-100.
2013: Derek M Fine; Joel E Gallant
Nephrotoxicity of antiretroviral agents: is the list getting longer?
The Journal of infectious diseases 2013;207(9):1349-51.
2012: Arata Honda; Koichi Kashiwazaki; Takafumi Tsunoda; Joel E Gallant; Todd T Brown
Short communication: CD4 cell count increases during successful treatment of Graves' disease with methimazole in HIV-infected patients on antiretroviral therapy.
AIDS research and human retroviruses 2012;28(12):1627-9.
2012: Steven J Reynolds; David Serwadda; Maria J Wawer; Joel E Gallant; Ronald H Gray; Wei Huang; Sarah E Hudelson; Oliver Laeyendecker; Gertrude Nakigozi; Kevin Newell; Thomas C Quinn; Susan H Eshleman
Antiretroviral drug susceptibility among HIV-infected adults failing antiretroviral therapy in Rakai, Uganda.
AIDS research and human retroviruses 2012;28(12):1739-44.
2012: Paul E Sax; Javier Szwarcberg; Kirsten White; David Wohl; Kitty Yale; Lijie Zhong; Andrew Zolopa; Andrew K Cheng; Calvin Cohen; Edwin DeJesus; Joel E Gallant; Brian P Kearney; Hui C Liu; Anthony Mills; Erin Quirk
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks.
Lancet 2012;379(9835):2439-48.
2012: Christine M Durand; Evelyn E Eisele; Joel E Gallant; Gabriel Ghiaur; Richard J Jones; Jun F Lai; Joseph B Margolick; S Alireza Rabi; Maria Salgado; Liang Shan; Janet D Siliciano; Richard F Ambinder; Hao Zhang; Robert Siliciano
HIV-1 DNA is detected in bone marrow populations containing CD4+ T cells but is not found in purified CD34+ hematopoietic progenitor cells in most patients on antiretroviral therapy.
The Journal of infectious diseases 2012;205(6):1014-8.
2012: Joel E Gallant; Renata O. Smith; Joey Wynn; Enid Vázquez
2012 HIV Drug Guide.
Positively aware : the monthly journal of the Test Positive Aware Network 2012;24(2):15-7, 22, 24-57 passim.
2012: Nadine E Chen; Joel E Gallant; Kathleen R Page
A systematic review of HIV/AIDS survival and delayed diagnosis among Hispanics in the United States.
Journal of immigrant and minority health / Center for Minority Public Health 2012;14(1):65-81.
2012: Joel E Gallant
Antiretroviral therapy in resource-limited settings: is there still a role for stavudine?
Antiviral therapy 2012;17(8):1507-9.
2012: Robert W Buckheit; Oluwaseun Falade-Nwulia; Joel E Gallant; Sarah Huculak; Karen A O'Connell; Maria Salgado; Robert Siliciano; Thomas M Williams; Tracy G Allen; Angela Alme; Joel N Blankson
Host factors dictate control of viral replication in two HIV-1 controller/chronic progressor transmission pairs.
Nature communications 2012;3():716.
2011: Joel E Gallant; Michael Horberg; Mari M Kitahata; E Byrd Quinlivan; James L Raper; Peter A Selwyn; Steven Bruce Williams; Adaora A Adimora; J Kevin Carmichael
Essential components of effective HIV care: a policy paper of the HIV Medicine Association of the Infectious Diseases Society of America and the Ryan White Medical Providers Coalition.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2011;53(11):1043-50.
2011: Myron S Cohen; Guy de Bruyn; Vanessa Elharrar; Joseph Eron; Susan H Eshleman; Max Essex; Thomas R Fleming; Joel E Gallant; Theresa Gamble; Sheela V Godbole; Beatriz Grinsztejn; James G Hakim; Diane Havlir; Irving F Hoffman; Mina C Hosseinipour; Nagalingeswaran Kumarasamy; Johnstone Kumwenda; Joseph Makhema; Kenneth H Mayer; Marybeth McCauley; Sanjay Mehendale; Lisa A Mills; Karin Nielsen-Saines; Jose H S Pilotto; Estelle Piwowar-Manning; Heather Ribaudo; Ian Sanne; Breno R Santos; Susan Swindells; Taha E Taha; Lei Wang; David Burns; David Celentano; Suwat Chariyalertsak; Ying Q Chen
Prevention of HIV-1 infection with early antiretroviral therapy.
The New England journal of medicine 2011;365(6):493-505.
2011: Joel E Gallant
A proper introduction.
Positively aware : the monthly journal of the Test Positive Aware Network 2011;23(2):13-5.
2011: Jean B Nachega; Marco Vitória; Michele Zeier; Michael J Mugavero; Joel E Gallant
Treatment simplification in HIV-infected adults as a strategy to prevent toxicity, improve adherence, quality of life and decrease healthcare costs.
Patient preference and adherence 2011;5():357-67.
2011: Richard D Moore; John G Bartlett; Joel E Gallant
Association between use of HMG CoA reductase inhibitors and mortality in HIV-infected patients.
PloS one 2011;6(7):e21843.
2010: Florencia Pereyra; Xiaoming Jia; Paul J McLaren; Amalio Telenti; Paul I W de Bakker; Bruce D Walker; Stephan Ripke; Chanson J Brumme; Sara L Pulit; Mary Carrington; Carl M Kadie; Jonathan M Carlson; David Heckerman; Robert R Graham; Robert M Plenge; Steven G Deeks; Lauren Gianniny; Gabriel Crawford; Jordan Sullivan; Elena Gonzalez; Leela Davies; Amy Camargo; Jamie M Moore; Nicole Beattie; Supriya Gupta; Andrew Thomas Crenshaw; Noël P Burtt; Candace Guiducci; Namrata Gupta; Xiaojiang Gao; Ying Qi; Yuko Yuki; Alicja Piechocka-Trocha; Emily Cutrell; Rachel Rosenberg; Kristin L Moss; Paul Lemay; Jessica O'Leary; Todd Schaefer; Pranshu Verma; Ildiko Toth; Brian Block; Brett Baker; Alissa Rothchild; Jeffrey Lian; Jacqueline Proudfoot; Donna Marie L Alvino; Seanna Vine; Marylyn M Addo; Todd M Allen; Marcus Altfeld; Matthew R Henn; Sylvie Le Gall; Hendrik Streeck; David W Haas; Daniel R Kuritzkes; Gregory K Robbins; Robert W Shafer; Roy M Gulick; Cecilia M Shikuma; Richard Haubrich; Sharon Riddler; Paul E Sax; Eric S Daar; Heather J Ribaudo; Brian Agan; Shanu Agarwal; Richard L Ahern; Brady L Allen; Sherly Altidor; Eric L Altschuler; Sujata Ambardar; Kathryn Anastos; Ben Anderson; Val Anderson; Ushan Andrady; Diana Antoniskis; David Bangsberg; Daniel Barbaro; William Barrie; J Bartczak; Simon Barton; Patricia Basden; Nesli Basgoz; Suzane Bazner; Nicholaos C Bellos; Anne M Benson; Judith Berger; Nicole F Bernard; Annette M Bernard; Christopher Birch; Stanley J Bodner; Robert K Bolan; Emilie T Boudreaux; Meg Bradley; James F Braun; Jon E Brndjar; Stephen J Brown; Katherine Brown; Sheldon T Brown; Jedidiah Burack; Larry M Bush; Virginia Cafaro; Omobolaji Campbell; John Campbell; Robert H Carlson; J Kevin Carmichael; Kathleen K Casey; Chris Cavacuiti; Gregory Celestin; Steven T Chambers; Nancy Chez; Lisa M Chirch; Paul J Cimoch; Daniel Cohen; Lillian E Cohn; Brian Conway; David A Cooper; Brian Cornelson; David T Cox; Michael V Cristofano; George Cuchural; Julie L Czartoski; Joseph M Dahman; Jennifer S Daly; Benjamin T Davis; Kristine Davis; Sheila M Davod; Edwin DeJesus; Craig A Dietz; Eleanor Dunham; Michael E Dunn; Todd B Ellerin; Joseph J Eron; John J W Fangman; Claire E Farel; Helen Ferlazzo; Sarah Fidler; Anita Fleenor-Ford; Renee Frankel; Kenneth A Freedberg; Neel K French; Jonathan D Fuchs; Jon D Fuller; Jonna Gaberman; Joel E Gallant; Rajesh T Gandhi; Efrain Garcia; Donald Garmon; Joseph C Gathe; Cyril R Gaultier; Wondwoosen Gebre; Frank D Gilman; Ian Gilson; Paul A Goepfert; Michael S Gottlieb; Claudia Goulston; Richard K Groger; T Douglas Gurley; Stuart Haber; Robin Hardwicke; W David Hardy; P Richard Harrigan; Trevor N Hawkins; Sonya Heath; Frederick M Hecht; W Keith Henry; Melissa Hladek; Robert P Hoffman; James M Horton; Ricky K Hsu; Gregory D Huhn; Peter Hunt; Mark J Hupert; Mark L Illeman; Hans Jaeger; Robert M Jellinger; Mina John; Jennifer A Johnson; Kristin L Johnson; Heather Johnson; Kay Johnson; Jennifer Joly; Wilbert C Jordan; Carol A Kauffman; Homayoon Khanlou; Robert K Killian; Arthur Y Kim; David D Kim; Clifford A Kinder; Jeffrey T Kirchner; Laura Kogelman; Erna Milunka Kojic; P Todd Korthuis; Wayne Kurisu; Douglas S Kwon; Melissa LaMar; Harry Lampiris; Massimiliano Lanzafame; Michael M Lederman; David M Lee; Jean M L Lee; Marah J Lee; Edward T Y Lee; Janice Lemoine; Jay A Levy; Josep M Llibre; Michael A Liguori; Susan J Little; Anne Y Liu; Alvaro J Lopez; Mono R Loutfy; Dawn Loy; Debbie Y Mohammed; Alan Man; Michael K Mansour; Vincent C Marconi; Martin Markowitz; Rui Marques; Jeffrey N Martin; Harold L Martin; Kenneth Hugh Mayer; M Juliana McElrath; Theresa A McGhee; Barbara H McGovern; Katherine McGowan; Dawn McIntyre; Gavin X Mcleod; Prema Menezes; Greg Mesa; Craig E Metroka; Dirk Meyer-Olson; Andy O Miller; Kate Montgomery; Karam C Mounzer; Ellen H Nagami; Iris Nagin; Ronald G Nahass; Margret O Nelson; Craig Nielsen; David L Norene; David H O'Connor; Bisola O Ojikutu; Jason Okulicz; Olakunle O Oladehin; Edward C Oldfield; Susan A Olender; Mario Ostrowski; William F Owen; Eunice Pae; Jeffrey Parsonnet; Andrew M Pavlatos; Aaron M Perlmutter; Michael N Pierce; Jonathan M Pincus; Leandro Pisani; Lawrence Jay Price; Laurie Proia; Richard C Prokesch; Heather Calderon Pujet; Moti Ramgopal; Almas Rathod; Michael Rausch; J Ravishankar; Frank S Rhame; Constance Shamuyarira Richards; Douglas D Richman; Berta Rodes; Milagros Rodriguez; Richard C Rose; Eric S Rosenberg; Daniel Rosenthal; Polly E Ross; David S Rubin; Elease Rumbaugh; Luis Saenz; Michelle R Salvaggio; William C Sanchez; Veeraf M Sanjana; Steven Santiago; Wolfgang Schmidt; Hanneke Schuitemaker; Philip M Sestak; Peter Shalit; William Shay; Vivian N Shirvani; Vanessa I Silebi; James M Sizemore; Paul R Skolnik; Marcia Sokol-Anderson; James M Sosman; Paul Stabile; Jack T Stapleton; Sheree Starrett; Francine Stein; Hans-Jurgen Stellbrink; F Lisa Sterman; Valerie E Stone; David R Stone; Giuseppe Tambussi; Randy A Taplitz; Ellen M Tedaldi; Amalio Telenti; William Theisen; Richard Torres; Lorraine Tosiello; Cecile Tremblay; Marc A Tribble; Phuong D Trinh; Alice Tsao; Peggy Ueda; Anthony Vaccaro; Emilia Valadas; Thanes J Vanig; Isabel Vecino; Vilma M Vega; Wenoah Veikley; Barbara H Wade; Charles Walworth; Chingchai Wanidworanun; Douglas J Ward; Daniel A Warner; Robert D Weber; Duncan Webster; Steve Weis; David A Wheeler; David J White; Ed Wilkins; Alan Winston; Clifford G Wlodaver; Angelique van't Wout; David P Wright; Otto O Yang; David L Yurdin; Brandon W Zabukovic; Kimon C Zachary; Beth Zeeman; Meng Zhao
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation.
Science (New York, N.Y.) 2010;330(6010):1551-7.
2010: Kim A Reiss; Justin R Bailey; Paul A Pham; Joel E Gallant
Raltegravir-induced cerebellar ataxia.
AIDS (London, England) 2010;24(17):2757.
2010: Pedro A Mendez-Tellez; Abdulla Damluji; Douglas Ammerman; ELIZABETH COLANTUONI; EDDY FAN; Jonathan Sevransky; Carl Shanholtz; Joel E Gallant; Peter Pronovost ; Dale M Needham
Human immunodeficiency virus infection and hospital mortality in acute lung injury patients.
Critical care medicine 2010;38(7):1530-5.
2010: Adam M Spivak; Emily R M Sydnor; Joel N Blankson; Joel E Gallant
Seronegative HIV-1 infection: a review of the literature.
AIDS (London, England) 2010;24(10):1407-14.
2010: Joseph B Margolick; Hejab Imteyaz; Joel E Gallant; Susan J Langan; Jason B Dinoso; Janet D Siliciano; Joel N Blankson; Tricia L Nilles; Kendall A Smith; LINDA APUZZO
Prolonged viral suppression without therapy in an HIV-1 seroconverter following early antiretroviral therapy and daily interleukin-2.
AIDS (London, England) 2010;24(6):932-5.
2010: Joel E Gallant
Mix and match. With as many as six drug categories, more than ever, how to treat HIV can become a matter of strategy.
Positively aware : the monthly journal of the Test Positive Aware Network 2010;21(2):18-9.
2010: Adam M Spivak; Tim P Brennan; Karen A O'Connell; Emily Sydnor; Thomas M Williams; Robert Siliciano; Joel E Gallant; Joel N Blankson
A case of seronegative HIV-1 infection.
The Journal of infectious diseases 2010;201(3):341-5.
2010: Joel E Gallant
What does the generalist need to know about HIV infection?
Advances in chronic kidney disease 2010;17(1):5-18.
2009: Joel E Gallant; Richard D Moore
Renal function with use of a tenofovir-containing initial antiretroviral regimen.
AIDS (London, England) 2009;23(15):1971-5.
2009: Judith A Aberg; Jonathan E Kaplan; Howard Libman; Patricia Emmanuel; Jean R Anderson; Valerie E Stone; James M Oleske; Judith S Currier; Joel E Gallant
Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine Association of the Infectious Diseases Society of America.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2009;49(5):651-81.
2009: Joel E Gallant
Routine HIV screening, Part 2: beyond testing and referral.
The AIDS reader 2009;19(6):211-2.
2009: Joel E Gallant
CROI 2009: a few key presentations on antiretroviral therapy.
The AIDS reader 2009;19(4):129-30, C3.
2009: Joel E Gallant
Preaching to the choir: advocating routine HIV testing.
The AIDS reader 2009;19(3):89-90.
2009: Joel E Gallant
HIV drug guide introduction. A brief description of the drug classes and how they work.
Positively aware : the monthly journal of the Test Positive Aware Network 2009;20(2):24-5.
2009: LINDA APUZZO; Florin Vaida; Joel E Gallant; Karin B Ernstrom; Susan J Little; Jean-Pierre Routy; Ann C Collier; Brian Conway; Martin H Markowitz; Frederick Hecht; Bruce D Walker; Elizabeth Connick; Joseph B Margolick
Tolerability and efficacy of PI versus NNRTI-based regimens in subjects receiving HAART during acute or early HIV infection.
Journal of acquired immune deficiency syndromes (1999) 2009;50(3):267-75.
2009: Philip Grant; Jonathan Taylor; Pat Cain; William Short; Joel E Gallant; Charles Farthing; Gary Thal; Eoin Coakley; Andrew R Zolopa
Maintaining reduced viral fitness and CD4 response in HIV-infected patients with viremia receiving a boosted protease inhibitor.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2009;48(5):680-2.
2009: Joel E Gallant
When to start antiretroviral therapy? NA-ACCORD stimulates the debate.
The AIDS reader 2009;19(2):49-50, 61.
2009: Lucy E Wilson; Joel E Gallant
HIV/AIDS: the management of treatment-experienced HIV-infected patients: new drugs and drug combinations.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2009;48(2):214-21.
2008: Joel E Gallant; Jonathan A Winston; Edwin DeJesus; Anton L Pozniak; Shan-Shan Chen; Andrew K Cheng; Jeffrey Enejosa
The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients.
AIDS (London, England) 2008;22(16):2155-63.
2008: Jean B Nachega; Michael Hislop; David Wesley Dowdy; Joel E Gallant; Richard E Chaisson; Leon Regensberg; Gary Maartens
Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in Southern African adults.
AIDS (London, England) 2008;22(16):2117-25.
2008: Joel E Gallant
Wellness checklist. Important things to consider when you're HIV-positive.
Positively aware : the monthly journal of the Test Positive Aware Network 2008;19(5):36-7.
2008: Joel E Gallant; José R Arribas
Antiretroviral rounds. Is that "one pill" treatment enough?
AIDS clinical care 2008;20(7):53-4.
2008: Christopher J Hoffmann; Joel E Gallant
Initial regimens for the treatment-naive patient: current understanding and practice.
The AIDS reader 2008;18(6):326-30, 336-8.
2008: Joel E Gallant
When to start antiretroviral therapy: a swinging pendulum?
Topics in HIV medicine : a publication of the International AIDS Society, USA 2008;16(2):82-8.
2008: S S Solomon; C S Hawcroft; P Narasimhan; R Subbaraman; A K Srikrishnan; A J Cecelia; M Suresh Kumar; Suniti Solomon; Joel E Gallant; David Celentano
Comorbidities among HIV-infected injection drug users in Chennai, India.
The Indian journal of medical research 2008;127(5):447-52.
2008: Yefei Han; Jun Lai; PATRICIA CROVO; Joel E Gallant; Thomas M Williams; Robert Siliciano; Joel N Blankson
The role of protective HCP5 and HLA-C associated polymorphisms in the control of HIV-1 replication in a subset of elite suppressors.
AIDS (London, England) 2008;22(4):541-4.
2008: Mariela Diaz-Linares; Enid Vázquez; Joel E Gallant; Martin Delaney
12th annual HIV drug guide.
Positively aware : the monthly journal of the Test Positive Aware Network 2008;19(1):19-48.
2008: Joel E Gallant
HIV drug guide introduction. A brief description of the drug classes and how they work.
Positively aware : the monthly journal of the Test Positive Aware Network 2008;19(1):18.
2008: Joel E Gallant
Antiretroviral therapy update. Everything you need to know, in a nutshell.
Positively aware : the monthly journal of the Test Positive Aware Network 2008;19(1):10-3.
2008: José Ramon Arribas; Anton L Pozniak; Joel E Gallant; Edwin DeJesus; Brian Gazzard; Rafael E Campo; Shan-Shan Chen; Damian McColl; Charles Holmes; Jeffrey Enejosa; John J Toole; Andrew K Cheng
Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis.
Journal of acquired immune deficiency syndromes (1999) 2008;47(1):74-8.
2007: Joel E Gallant
Making sense of blips.
The Journal of infectious diseases 2007;196(12):1729-31.
2007: Joel E Gallant
Should antiretroviral therapy be started earlier?
Current HIV/AIDS reports 2007;4(2):53-9.
2007: Christopher J Hoffman; Joel E Gallant
When and how to use tipranavir and darunavir.
The AIDS reader 2007;17(4):194-8, 201.
2007: Richard Haubrich; Dan Berger; Philippe Chiliade; Amy Colson; Marcus Conant; Joel E Gallant; Timothy Wilkin; Jeffrey Nadler; Gerald Pierone; Michael Saag; Ben van Baelen; Eric Lefebvre
Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients.
AIDS (London, England) 2007;21(6):F11-8.
2007: Janet D Siliciano; Jun Lai; Marc Callender; Eleanor Pitt; Hao Zhang; Joseph B Margolick; Joel E Gallant; Joseph Cofrancesco; Richard D Moore; Stephen J Gange; Robert Siliciano
Stability of the latent reservoir for HIV-1 in patients receiving valproic acid.
The Journal of infectious diseases 2007;195(6):833-6.
2007: Joel E Gallant
Report from Los Angeles: the 14th Conference on Retroviruses and Opportunistic Infections (CROI). Management of treatment-naïve patients.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 2007;19(2):1-3, 12.
2007: Joel E Gallant
Approach to the treatment-experienced patient.
Infectious disease clinics of North America 2007;21(1):85-102, viii-ix.
2007: Paul E Sax; Joel E Gallant; Paul Klotman
Renal safety of tenofovir disoproxil fumarate.
The AIDS reader 2007;17(2):90-2, 99-104, C3.
2007: Joel E Gallant
Drug resistance after failure of initial antiretroviral therapy in resource-limited countries.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2007;44(3):453-5.
2007: James Riddell IV; Daniel Kaul; Petros C Karakousis; Joel E Gallant; Jennifer Mitty; Powel Kazanjian
Mycobacterium avium complex immune reconstitution inflammatory syndrome: long term outcomes.
Journal of translational medicine 2007;5():50.
2007: Joel E Gallant
Antiretroviral update from the 46th ICAAC.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 2007;19(1):1-3, 12.
2006: Anton L Pozniak; Joel E Gallant; Edwin DeJesus; José Ramon Arribas; Brian Gazzard; Rafael E Campo; Shan-Shan Chen; Damian McColl; Jeffrey Enejosa; John J Toole; Andrew K Cheng
Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis.
Journal of acquired immune deficiency syndromes (1999) 2006;43(5):535-40.
2006: Joel E Gallant
The M184V mutation: what it does, how to prevent it, and what to do with it when it's there.
The AIDS reader 2006;16(10):556-9.
2006: Mohamed G Atta; Joel E Gallant; M Hafizur Rahman; Nagapradeep Nagajothi; Lorraine C Racusen; Paul J Scheel; Derek M Fine
Antiretroviral therapy in the treatment of HIV-associated nephropathy.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2006;21(10):2809-13.
2006: Xiuhong Li; Haitao Chu; Joel E Gallant; Donald R Hoover; Wendy Mack; Joan S Chmiel; ALVARO MUNOZ
Bimodal virological response to antiretroviral therapy for HIV infection: an application using a mixture model with left censoring.
Journal of epidemiology and community health 2006;60(9):811-8.
2006: Joel E Gallant
Editorial comment: predictors of response--updating the traditional list.
The AIDS reader 2006;16(8):432-3.
2006: Michelle Estrella; Derek M Fine; Joel E Gallant; M Hafizur Rahman; Nagapradeep Nagajothi; Lorraine C Racusen; Paul J Scheel; Mohamed G Atta
HIV type 1 RNA level as a clinical indicator of renal pathology in HIV-infected patients.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2006;43(3):377-80.
2006: Justin R Bailey; Ahmad R Sedaghat; Tara L Kieffer; Timothy Brennan; Patricia K Lee; Megan Wind-Rotolo; Christine M Haggerty; Ashrit R Kamireddi; Yi Liu; Jessica Lee; Deborah Persaud; Joel E Gallant; Joseph Cofrancesco; Thomas C Quinn; Claus O Wilke; Stuart C Ray; Janet D Siliciano; Richard E Nettles; Robert Siliciano
Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells.
Journal of virology 2006;80(13):6441-57.
2006: Paul A Pham; Joel E Gallant
Tenofovir disoproxil fumarate for the treatment of HIV infection.
Expert opinion on drug metabolism & toxicology 2006;2(3):459-69.
2006: Joel E Gallant
Editorial comment: treating the experienced patient--when and how to use new agents.
The AIDS reader 2006;16(5):274-5.
2006: Beulah P Sabundayo; Julie H McArthur; Susan J Langan; Joel E Gallant; Joseph B Margolick
High frequency of highly active antiretroviral therapy modifications in patients with acute or early human immunodeficiency virus infection.
Pharmacotherapy 2006;26(5):674-81.
2006: Richard E Nettles; Tara L Kieffer; Teresa Parsons; James Johnson; Joseph Cofrancesco; Joel E Gallant; Kathryn Carson; Robert Siliciano; Charles Flexner
Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2006;42(8):1189-96.
2006: Sam M Mbulaiteye; Jonnae O Atkinson; Denise Whitby; David A Wohl; Joel E Gallant; Scott Royal; James J Goedert; Charles S Rabkin
Risk factors for human herpesvirus 8 seropositivity in the AIDS Cancer Cohort Study.
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 2006;35(4):442-9.
2006: Joel E Gallant; Edwin DeJesus; José Ramon Arribas; Anton L Pozniak; Brian Gazzard; Rafael E Campo; Biao Lu; Damian McColl; Steven Chuck; Jeffrey Enejosa; John J Toole; Andrew K Cheng
Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.
The New England journal of medicine 2006;354(3):251-60.
2006: Joel E Gallant
Antiretroviral news from the 10th EACS, Dublin.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 2006;18(1):5-7.
2006: Joel E Gallant
Antiretroviral news from the 45th ICAAC.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 2006;18(1):1-4.
2005: Joel E Gallant
Antiretroviral drug resistance and resistance testing.
Topics in HIV medicine : a publication of the International AIDS Society, USA 2005;13(5):138-42.
2005: Joel E Gallant; Allan Rodriguez; Winkler G Weinberg; Benjamin Young; Daniel S. Berger; Michael L Lim; Qiming Liao; Lisa Ross; Judy Johnson; Mark Shaefer
Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects.
The Journal of infectious diseases 2005;192(11):1921-30.
2005: Joel E Gallant
False positive viral load results: recent problems and solutions.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 2005;17(6):1, 4.
2005: Richard E Nettles; Tara L Keiffer; Joseph Cofrancesco; Joel E Gallant; Thomas C Quinn; J Brooks Jackson; Charles Flexner; Kathryn Carson; Albert W Wu; Robert Siliciano
Psychological distress and physical pain appear to have no short-term adverse impact on plasma HIV-1 RNA levels in patients on successful HAART.
HIV clinical trials 2005;6(5):262-71.
2005: Joel E Gallant
3rd IAS conference: initial therapy, switching, and new strategies.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 2005;17(5):1-3, 12.
2005: Joel E Gallant; Robert Shafer
Antiretroviral rounds. Virologic failure: true or false?
AIDS clinical care 2005;17(9):84-5.
2005: Eric Nawar; Sam M Mbulaiteye; Joel E Gallant; David A Wohl; Marianne Ardini; Tabitha Hendershot; James J Goedert; Charles S Rabkin
Risk factors for Kaposi's sarcoma among HHV-8 seropositive homosexual men with AIDS.
International journal of cancer. Journal international du cancer 2005;115(2):296-300.
2005: Joel E Gallant
Approach to the treatment-experienced patient.
Current HIV/AIDS reports 2005;2(2):83-9.
2005: Joel E Gallant; Michelle A Parish; Jeanne C Keruly; Richard D Moore
Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2005;40(8):1194-8.
2005: Hassane Izzedine; Jean-Sébastien Hulot; Daniel Vittecoq; Joel E Gallant; Schlomo Staszewski; Vincent Launay-Vacher; Andrew Cheng; Gilbert Deray
Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2005;20(4):743-6.
2005: Joel E Gallant
Treatment of naïve patients: update from the 12th CROI.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 2005;17(2):4-5.
2005: Richard E Nettles; Tara L Kieffer; Patty Kwon; Daphne Monie; Yefei Han; Teresa Parsons; Joseph Cofrancesco; Joel E Gallant; Thomas C Quinn; J Brooks Jackson; Charles Flexner; Kathryn Carson; Stuart C Ray; Deborah Persaud; Robert Siliciano
Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART.
JAMA : the journal of the American Medical Association 2005;293(7):817-29.
2005: Joel E Gallant
Antiretroviral therapy update from the 44th ICAAC.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 2005;17(1):1-3, 7.
2004: Patrick M Tarwater; Joel E Gallant; John W Mellors; Mary E Gore; John Phair; Roger Detels; Joseph B Margolick; ALVARO MUNOZ
Prognostic value of plasma HIV RNA among highly active antiretroviral therapy users.
AIDS (London, England) 2004;18(18):2419-23.
2004: Joel E Gallant
Editorial comment: strategies for success--a return to "hit early"?
The AIDS reader 2004;14(12):662-3.
2004: Joel E Gallant
XV International AIDS Conference in Bangkok: antiretroviral therapy.
HIV clinical trials 2004;5(6):434-40.
2004: Joel E Gallant
The choice of the nucleoside backbone in initial therapy.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 2004;16(6):1-6, 10.
2004: Joel E Gallant
Protease-inhibitor boosting in the treatment-experienced patient.
AIDS reviews 2004;6(4):226-33.
2004: Richard E Nettles; Tara L Kieffer; Rachel P Simmons; Joseph Cofrancesco; Richard D Moore; Joel E Gallant; Deborah Persaud; Robert Siliciano
Genotypic resistance in HIV-1-infected patients with persistently detectable low-level viremia while receiving highly active antiretroviral therapy.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2004;39(7):1030-7.
2004: Joel E Gallant
XV International AIDS Conference in Bangkok: antiretroviral therapy.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 2004;16(5):1-6.
2004: Judith A Aberg; Joel E Gallant; Jean R Anderson; James M Oleske; Howard Libman; Judith S Currier; Valerie E Stone; Jonathan E Kaplan
Primary care guidelines for the management of persons infected with human immunodeficiency virus: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2004;39(5):609-29.
2004: Joel E Gallant
The ideal nucleoside/nucleotide backbone.
Journal of acquired immune deficiency syndromes (1999) 2004;37 Suppl 1():S44-51.
2004: Joel E Gallant
Current perspectives on the nucleoside/nucleotide components of combination antiretroviral therapy.
Journal of acquired immune deficiency syndromes (1999) 2004;37 Suppl 1():S1.
2004: Kelly A Gebo; Joel E Gallant; Jeanne C Keruly; Richard D Moore
Absolute CD4 vs. CD4 percentage for predicting the risk of opportunistic illness in HIV infection.
Journal of acquired immune deficiency syndromes (1999) 2004;36(5):1028-33.
2004: Gregory M Lucas; Joel E Gallant; Richard D Moore
Relationship between drug resistance and HIV-1 disease progression or death in patients undergoing resistance testing.
AIDS (London, England) 2004;18(11):1539-48.
2004: Joel E Gallant
HIV infection--how to lower your risk.
American family physician 2004;70(2):307-8.
2004: Joel E Gallant
HIV counseling, testing, and referral.
American family physician 2004;70(2):295-302.
2004: Joel E Gallant; Schlomo Staszewski; Anton L Pozniak; Edwin DeJesus; Jamal Muhamad A H Suleiman; Michael D Miller; Dion F Coakley; Biao Lu; John J Toole; Andrew K Cheng
Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.
JAMA : the journal of the American Medical Association 2004;292(2):191-201.
2004: Joel E Gallant
Editorial comment: thoughts on the once-daily-dosing bandwagon.
The AIDS reader 2004;14(6):330-1.
2004: Ajay K Sethi; David Celentano; Stephen J Gange; Joel E Gallant; David Vlahov; Homayoon Farzadegan
High-risk behavior and potential transmission of drug-resistant HIV among injection drug users.
Journal of acquired immune deficiency syndromes (1999) 2004;35(5):503-10.
2004: Joel N Blankson; Joel E Gallant
Early treatment of HIV.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 2004;16(2):14.
2004: Joel E Gallant
Report from San Francisco: The 11th Conference on Retroviruses and Opportunistic Infections (CROI). Antiretroviral therapy: the naïve patient.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 2004;16(2):1-4.
2004: Deborah Persaud; Joel E Gallant
Report from San Francisco: The 11th Conference on Retroviruses and Opportunistic Infections (CROI). The tenacity of NNRTI drug resistance.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 2004;16(2):1, 5, 15.
2003: Joel E Gallant; Peter Gerondelis; Mark A Wainberg; Nancy S Shulman; Richard Haubrich; Marty St Clair; E Randall Lanier; Nicholas S Hellmann; Douglas D Richman
Nucleoside and nucleotide analogue reverse transcriptase inhibitors: a clinical review of antiretroviral resistance.
Antiviral therapy 2003;8(6):489-506.
2003: Patrick M Tarwater; Michelle Parish; Joel E Gallant
Prolonged treatment interruption after immunologic response to highly active antiretroviral therapy.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2003;37(11):1541-8.
2003: Joel E Gallant
Antiretroviral news from the Chicago: the 43rd ICAAC.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 2003;15(6):1-4.
2003: Ajay K Sethi; David Celentano; Stephen J Gange; Richard D Moore; Joel E Gallant
Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2003;37(8):1112-8.
2003: Joel E Gallant; Paul A Pham
Tenofovir disoproxil fumarate (Viread) for the treatment of HIV infection.
Expert review of anti-infective therapy 2003;1(3):415-22.
2003: Joel E Gallant; Stan Deresinski
Tenofovir disoproxil fumarate.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2003;37(7):944-50.
2003: Joel E Gallant
Antiretroviral therapy update from the 2nd IAS Conference.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 2003;15(5):1-4.
2003: Joel E Gallant
AACTG A5095, Trizivir, and the role of all-nucleoside regimens: an editorial.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 2003;15(4):1-2.
2003: Joel E Gallant
The optimal use of enfuvirtide.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 2003;15(3):1-3.
2003: Jacob P Lalezari; Joseph J Eron; Margrit Carlson; Calvin Cohen; Edwin DeJesus; Roberto C Arduino; Joel E Gallant; Paul A Volberding; Robert L Murphy; Fred Valentine; Emily L Nelson; Prakash Sista; Alex Dusek; J. Michael Kilby
A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy.
AIDS (London, England) 2003;17(5):691-8.
2003: J Brooks Jackson; Scott Barnett; Estelle Piwowar-Manning; LINDA APUZZO; Charles Raines; Craig W Hendrix; Fayez M Hamzeh; Joel E Gallant
A phase I/II study of nevirapine for pre-exposure prophylaxis of HIV-1 transmission in uninfected subjects at high risk.
AIDS (London, England) 2003;17(4):547-53.
2003: Joel E Gallant
Drug resistance and treatment of experienced patients.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 2003;15(2):8-9.
2003: Joel E Gallant
Report from Boston: the 10th Conference on Retroviruses and Opportunistic Infections (CROI).
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 2003;15(2):1-2, 11.
2003: Daniel R Kuritzkes; Brian A Boyle; Joel E Gallant; Kathleen E Squires; Andrew R Zolopa
Current management challenges in HIV: antiretroviral resistance.
The AIDS reader 2003;13(3):133-5, 138-42.
2003: Joel E Gallant
Tipranavir.
Drugs 2003;63(15):1619-20.
2003: Joel E Gallant
Current status of antiretroviral treatment interruption and intermittent therapy strategies.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 2003;15(1):8-9, 16.
2002: Nancy S Shulman; Andrew R Zolopa; Diane V Havlir; Ann Hsu; Cheryl Renz; Sheila Boller; Ping Jiang; Richard Rode; Joel E Gallant; Elizabeth Race; Dale J Kempf; Eugene Sun
Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia.
Antimicrobial agents and chemotherapy 2002;46(12):3907-16.
2002: Joel E Gallant
Initial therapy of HIV infection.
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 2002;25(3):317-33.
2002: Joel E Gallant
Report from ICAAC: new drugs and antiretroviral therapy for naïve patients.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 2002;14(6):1-3, 7.
2002: Pablo Barreiro; Teresa García-Benayas; Vincent Soriano; Joel E Gallant
Simplification of antiretroviral treatment--how to sustain success, reduce toxicity and ensure adherence avoiding PI use.
AIDS reviews 2002;4(4):233-41.
2002: Joel E Gallant
Current status of antiretroviral treatment interruption and intermittent therapy strategies.
MedGenMed : Medscape general medicine 2002;4(3):19.
2002: Joel E Gallant
Drug resistance and the treatment of experienced patients.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 2002;14(5):1, 5-7, 16.
2002: Joel N Blankson; Joel E Gallant; Thomas C Quinn; John G Bartlett; Robert Siliciano
Loss of HIV-1-specific immunity during treatment interruption in 2 chronically infected patients.
JAMA : the journal of the American Medical Association 2002;288(2):162-4.
2002: Richard E Chaisson; Kelly A Gebo; Charles Flexner; Joel E Gallant; Gregory M Lucas; John G Bartlett
Selected topics from the 9th Conference on Retroviruses and Opportunistic Infections.
HIV clinical trials 2002;3(4):333-49.
2002: J. Michael Kilby; Jacob P Lalezari; Joseph J Eron; Margrit Carlson; Calvin Cohen; Roberto C Arduino; Jeffrey C Goodgame; Joel E Gallant; Paul A Volberding; Robert L Murphy; Fred Valentine; Michael S Saag; Emily L Nelson; Prakash Sista; Alex Dusek
The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults.
AIDS research and human retroviruses 2002;18(10):685-93.
2002: Joel E Gallant
New drugs in clinical development and treatment of naive patients.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 2002;14(2):10-1.
2002: Joel E Gallant
Antiretroviral news from the 41st ICAAC.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 2002;14(1):1-5.
2001: Joel E Gallant
My doc wants me to have another genotype panel. The HMO will not pay for this test. Last time, it cost my lover and me more than $900 from a lab in California. Do you know of some less costly providers of genotype tests? $900 is a lot of money! And do you have any information on when (if ever) the FDA is going to approve these tests, so the insurance companies will pay for them?
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 2001;13(6):11.
2001: Joel E Gallant
After a person has built resistance to a drug and then goes on other drugs for a while, is it possible that the virus loses its resistance to the first drug after not being in their system for awhile, or will the virus be resistant to that drug for the rest of his/her life?
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 2001;13(6):11.
2001: Joel E Gallant
AIDS freak-time to give up?
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 2001;13(6):11.
2001: Joel E Gallant
What is the latest news on structured interrupted treatment? Should a healthy HIV positive person consider an STI? What are the risks involved and for how long should the meds be interrupted? Is there any chance of developing resistance?
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 2001;13(6):10.
2001: David Celentano; Noya Galai; A K Sethi; Nina G Shah; Steffanie A Strathdee; David Vlahov; Joel E Gallant
Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users.
AIDS (London, England) 2001;15(13):1707-15.
2001: Joel E Gallant
Report from Buenos Aires on new drugs.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 2001;13(5):8, 16.
2001: Joel E Gallant
Report from Buenos Aires: the 1st IAS Conference on HIV Pathogenesis and Treatment.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 2001;13(5):1-7, 15.
2001: John G Bartlett; Joel E Gallant
Recommendations for HIV-positive inmates.
Positively aware : the monthly journal of the Test Positive Aware Network 2001;12(4):30-1.
2001: Joel E Gallant
The Moore News and The Hopkins HIV Report: a time capsule: 1989-2001.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 2001;13(4):7, 10-1, 15.
2001: Joel E Gallant
Antiretroviral therapy: naïve patients and early therapy.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 2001;13(2):3-4, 15.
2001: Joel E Gallant
New antiretroviral agents.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 2001;13(2):2, 16.
2001: Gregory M Lucas; T R Sterling; John G Bartlett; Joel E Gallant
Selected topics from the 38th annual meeting of the Infectious Diseases Society of America, September 7-10, 2000, New Orleans, Louisiana and selected topics from the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17-20, 2000, Toronto, Ontario, Canada.
HIV clinical trials 2001;2(2):171-82.
2001: Joel N Blankson; Joel E Gallant; Robert Siliciano
Proliferative responses to human immunodeficiency virus type 1 (HIV-1) antigens in HIV-1-infected patients with immune reconstitution.
The Journal of infectious diseases 2001;183(4):657-61.
2000: Charles Raines; Charles Flexner; Eugene Sun; ME Heath-Chiozzi; R H Lewis; C Fields; Carl O Deetz; LINDA APUZZO; Susan H Eshleman; J Brooks Jackson; Joel E Gallant
Safety, tolerability, and antiretroviral effects of ritonavir-nelfinavir combination therapy administered for 48 weeks.
Journal of acquired immune deficiency syndromes (1999) 2000;25(4):322-8.
2000: Joel E Gallant
Antiretroviral news from ICAAC 2000.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 2000;12(5):8-9, 11.
2000: David W Haas; Eduardo G Arathoon; M A Thompson; R de Jesus Pedro; Joel E Gallant; David E Uip; Jeff Currier; L M Noriega; DS Lewi; P Uribe; L Benetucci; Pedro Cahn; D Paar; A C White; A C Collier; C H Ramirez-Ronda; C Harvey; M O Chung; D Mehrotra; Jeffrey A Chodakewitz; B Y Nguyen
Comparative studies of two-times-daily versus three-times-daily indinavir in combination with zidovudine and lamivudine.
AIDS (London, England) 2000;14(13):1973-8.
2000: Joel E Gallant
Antiretroviral therapy.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 2000;12(4):2-3, 14-5.
2000: James Hellinger; Calvin J Cohen; A J Stein; Joel E Gallant; J Gathe; Philip Keiser
Efficacy of nelfinavir in patients switched from ritonavir/saquinavir combination antiretroviral therapy.
HIV clinical trials 2000;1(2):25-8.
2000: Joel E Gallant
Strategies for long-term success in the treatment of HIV infection.
JAMA : the journal of the American Medical Association 2000;283(10):1329-34.
2000: Joel E Gallant
Antiretroviral therapy in naïve patients.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 2000;12(2):1, 6-7.
2000: Joel E Gallant
Drug Guide 2000: the antiretroviral agents.
Positively aware : the monthly journal of the Test Positive Aware Network 2000;11(1):30-1.
1999: W G Powderly; Joel E Gallant; M A Ghannoum; K H Mayer; E E Navarro; J R Perfect
Oropharyngeal candidiasis in patients with HIV: suggested guidelines for therapy.
AIDS research and human retroviruses 1999;15(18):1619-23.
1999: Joel E Gallant
Antiretroviral therapy.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 1999;11(6):1, 4-5, 8-9.
1999: Joel E Gallant
Therapy for the treatment-experienced patient.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 1999;11(5):1, 6-7, 14-5.
1999: C S Hall; Charles Raines; S H Barnett; Richard D Moore; Joel E Gallant
Efficacy of salvage therapy containing ritonavir and saquinavir after failure of single protease inhibitor-containing regimens.
AIDS (London, England) 1999;13(10):1207-12.
1999: Joel E Gallant
Antiretroviral therapy in the treatment-experienced patient.
The AIDS reader 1999;9(4):284-91.
1999: Diana Finzi; Joel N Blankson; Janet D Siliciano; Joseph B Margolick; Karen Chadwick; Theodore C Pierson; K Smith; Julianna Lisziewicz; F Lori; Charles Flexner; Thomas C Quinn; Richard E Chaisson; E Rosenberg; B Walker; Stephen J Gange; Joel E Gallant; Robert Siliciano
Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy.
Nature medicine 1999;5(5):512-7.
1999: Joel E Gallant
New antiretroviral agents.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 1999;11(2):3, 12.
1999: Joel E Gallant
Antiretroviral therapy in the experienced patient.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 1999;11(2):1, 4, 9, 16.
1999: Joel E Gallant; Richard E Chaisson; Jeanne C Keruly; Richard D Moore
Stavudine in zidovudine (ZDV)-experienced compared with ZDV-naive patients.
AIDS (London, England) 1999;13(2):225-9.
1999: Joel E Gallant
HIV antiretroviral agents.
Positively aware : the monthly journal of the Test Positive Aware Network 1999;10(1):25.
1999: Joel E Gallant
The new drugs and how to use them.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 1999;11(1):2, 7.
1998: Joel E Gallant
Antiretroviral therapy: rehashes, leftovers, and a pinch of new data.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 1998;10(6):1, 4, 9-11.
1998: Joel E Gallant; Richard E Chaisson; Richard D Moore
The effect of adjunctive corticosteroids for the treatment of Pneumocystis carinii pneumonia on mortality and subsequent complications.
Chest 1998;114(5):1258-63.
1998: Joel E Gallant
Antiretroviral news.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 1998;10(5):1, 4-7, 11.
1998: Joel E Gallant
A review of dual protease inhibitor therapy.
The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service 1998;10(3):1, 4-5.
1998: Joel E Gallant
Antiretroviral therapy: coping with failure, planning for success.
Positively aware : the monthly journal of the Test Positive Aware Network 1998;9(3):51-2, 55-7.
1998: Joel E Gallant; D S Block
Adherence to antiretroviral regimens in HIV-infected patients: results of a survey among physicians and patients.
Journal of the International Association of Physicians in AIDS Care 1998;4(5):32-5.
1998: Joel E Gallant
When to switch your drug combo.
Positively aware : the monthly journal of the Test Positive Aware Network 1998;9(1):29.
1998: Richard E Chaisson; Joel E Gallant; Jeanne C Keruly; Richard D Moore
Impact of opportunistic disease on survival in patients with HIV infection.
AIDS (London, England) 1998;12(1):29-33.
1997: Diana Finzi; Monika Hermankova; Theodore C Pierson; Lucy Minnich Carruth; Christopher Buck; Richard E Chaisson; Thomas C Quinn; Karen Chadwick; Joseph B Margolick; Ron Brookmeyer; Joel E Gallant; M Markowitz; D D Ho; D D Richman; Robert Siliciano
Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy.
Science (New York, N.Y.) 1997;278(5341):1295-300.
1997: V Pons; D Greenspan; F Lozada-Nur; L McPhail; Joel E Gallant; A Tunkel; C C Johnson; J McCarty; H Panzer; M Levenstein; A Barranco; S Green
Oropharyngeal candidiasis in patients with AIDS: randomized comparison of fluconazole versus nystatin oral suspensions.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1997;24(6):1204-7.
1997: Emily J Erbelding; Richard E Chaisson; Joel E Gallant; Richard D Moore
Acyclovir in combination with zidovudine does not prolong survival in advanced HIV disease.
Antiviral therapy 1997;2(2):71-7.
1997: Joel E Gallant
When to start therapy--and what to start with.
Positively aware : the monthly journal of the Test Positive Aware Network 1997;8(1):22-3.
1997: J R Maenza; William G Merz; MJ Romagnoli; Jeanne C Keruly; Richard D Moore; Joel E Gallant
Infection due to fluconazole-resistant Candida in patients with AIDS: prevalence and microbiology.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1997;24(1):28-34.
1996: L W Cheever; Richard E Chaisson; Joel E Gallant
Prophylaxis against opportunistic infections in patients infected with the human immunodeficiency virus.
The Western journal of medicine 1996;165(1-2):67-73.
1996: Richard E Chaisson; Jeanne C Keruly; S McAvinue; Joel E Gallant; Richard D Moore
Effects of an incentive and education program on return rates for PPD test reading in patients with HIV infection.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1996;11(5):455-9.
1996: Joel E Gallant; A H Ko
Cavitary pulmonary lesions in patients infected with human immunodeficiency virus.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1996;22(4):671-82.
1996: J R Maenza; Jeanne C Keruly; Richard D Moore; Richard E Chaisson; William G Merz; Joel E Gallant
Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients.
The Journal of infectious diseases 1996;173(1):219-25.
1995: A H Ko; D L Thomas; Joel E Gallant
Non-Hodgkin's lymphoma and Kaposi's sarcoma causing cavitary lung lesions in a patient with AIDS: an HIV-associated collision tumor.
AIDS (London, England) 1995;9(10):1195-7.
1995: Joel E Gallant; Richard D Moore; Jeanne C Keruly; D D Richman; Richard E Chaisson
Lack of association between acyclovir use and survival in patients with advanced human immunodeficiency virus disease treated with zidovudine. Zidovudine Epidemiology Study Group.
The Journal of infectious diseases 1995;172(2):346-52.
1995: Joel E Gallant; S M McAvinue; Richard D Moore; John G Bartlett; D L Stanton; Richard E Chaisson
The impact of prophylaxis on outcome and resource utilization in Pneumocystis carinii pneumonia.
Chest 1995;107(4):1018-23.
1995: Joel E Gallant
Infectious complications of HIV disease.
Emergency medicine clinics of North America 1995;13(1):73-104.
1994: Mark A Jacobson; Joel E Gallant; L H Wang; D Coakley; S Weller; D Gary; L Squires; M L Smiley; M R Blum; J Feinberg
Phase I trial of valaciclovir, the L-valyl ester of acyclovir, in patients with advanced human immunodeficiency virus disease.
Antimicrobial agents and chemotherapy 1994;38(7):1534-40.
1994: Joel E Gallant; Richard D Moore; Richard E Chaisson
Prophylaxis for opportunistic infections in patients with HIV infection.
Annals of internal medicine 1994;120(11):932-44.
1994: Joel E Gallant; Richard D Moore; D D Richman; Jeanne C Keruly; Richard E Chaisson
Risk factors for Kaposi's sarcoma in patients with advanced human immunodeficiency virus disease treated with zidovudine. Zidovudine Epidemiology Study Group.
Archives of internal medicine 1994;154(5):566-72.
1993: Joel E Gallant; Lois Eldred; JO LESLIE; Richard E Chaisson; Thomas C Quinn
Impact of the 1993 revision of the CDC case definition on the performance of the WHO and PAHO clinical case definitions for AIDS.
AIDS (London, England) 1993;7(10):1396-7.
1993: Richard E Chaisson; D L Stanton; Joel E Gallant; S Rucker; John G Bartlett; Richard D Moore
Impact of the 1993 revision of the AIDS case definition on the prevalence of AIDS in a clinical setting.
AIDS (London, England) 1993;7(6):857-62.
1992: Joel E Gallant; Richard D Moore; D D Richman; Jeanne C Keruly; Richard E Chaisson
Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group.
The Journal of infectious diseases 1992;166(6):1223-7.
1992: Joel E Gallant; P S Mueller; justin charles mcarthur; Richard E Chaisson
Intramedullary tuberculoma in a patient with HIV infection.
AIDS (London, England) 1992;6(8):889-91.
1992: Joel E Gallant; J Somani; Richard E Chaisson; D Stanton; M Smith; Thomas C Quinn
Diagnostic accuracy of three clinical case definitions for advanced HIV disease.
AIDS (London, England) 1992;6(3):295-9.
1991: C M Szych; S M Rotter; Joel E Gallant
Papules and nodules in a patient with the acquired immunodeficiency syndrome and recurrent cryptococcal meningitis. Bacillary angiomatosis or epithelioid angiomatosis.
Archives of dermatology 1991;127(12):1832-3, 1835-6.
1991: Joel E Gallant; E Hoehn-Saric; M D Smith
Respiratory insufficiency from dapsone-induced methemoglobinemia.
AIDS (London, England) 1991;5(11):1392-3.
1988: Joel E Gallant; R E Enriquez; K L Cohen; L W Hammers
Pneumocystis carinii thyroiditis.
The American journal of medicine 1988;84(2):303-6.